Iris Vance
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Iris Vance has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Kara Wegermann
Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, NC
1 shared publication - Sandra Au
Duke University School of Medicine, Duke University Medical Center, Durham, NC, USA
1 shared publication - Wei Chen
Duke University Durham North Carolina USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (10) , e01539
A Case of Immune Checkpoint Inhibitor–Induced Duodenitis
Immune checkpoint inhibitors improve patient survival in multiple cancers, but immune-related adverse events, including new immunologic conditions arising during therapy, pose a significant challenge. Gastrointestinal immune-related adverse events, although common, exhibit diverse presentations. We present a case of duodenitis resembling celiac disease because of the anti–programmed cell death protein-1 antibody, pembrolizumab. Despite diagnostic uncertainty and therapeutic interventions, including gluten-free diet, symptoms stabilized even with resuming gluten. In addition, endoscopic abnormalities after pembrolizumab therapy have neither progressed nor completely resolved. This case underscores the need for investigation into the pathogenesis of immune checkpoint inhibitor–induced duodenitis, with implications for care of patients on immunotherapies.
- 1 October 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (10) , e01539
Open AccessA Case of Immune Checkpoint Inhibitor–Induced Duodenitis
Immune checkpoint inhibitors improve patient survival in multiple cancers, but immune-related adverse events, including new immunologic conditions arising during therapy, pose a significant challenge. Gastrointestinal immune-related adverse events, although common, exhibit diverse presentations. We present a case of duodenitis resembling celiac disease because of the anti–programmed cell death protein-1 antibody, pembrolizumab. Despite diagnostic uncertainty and therapeutic interventions, including gluten-free diet, symptoms stabilized even with resuming gluten. In addition, endoscopic abnormalities after pembrolizumab therapy have neither progressed nor completely resolved. This case underscores the need for investigation into the pathogenesis of immune checkpoint inhibitor–induced duodenitis, with implications for care of patients on immunotherapies.